Vincent Milano
Vincent Milano's purchase track record
Vincent Milano has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/20/2024 | BCRX | $94K | +28.2% | +15.2% | +11.0% |
| 11/24/2021 | BCRX | $91K | +33.6% | -29.6% | -15.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
ACRS Not Highlighted in Recent Pre‑Market Moves. In the past week, pre‑market activity focused on large financial names and a list of 20 stocks, but Aclaris Therapeutics was not mentioned. The moves in big banks and other sectors could influence overall market sentiment, which may affect smaller biotech names like ACRS. No direct company news was reported, so the impact is limited at this time.
Transaction History
| BCRX | ▲ Buy | Grant | 1,159 | $11K | 8/31/2026 | View on chart |
| BCRX | ▲ Buy | Grant | 15,294 | $0 | 6/11/2026 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 11,580 | — | 6/5/2026 | View on chart |
| BCRX | ▲ Buy | Grant | 1,122 | $10K | 5/29/2026 | View on chart |
| BCRX | ▲ Buy | Grant | 848 | $7K | 2/27/2026 | View on chart |
| BCRX | ▲ Buy | Grant | 783 | $6K | 11/28/2025 | View on chart |
| BCRX | ▲ Buy | Grant | 676 | $6K | 8/29/2025 | View on chart |
| BCRX | ▲ Buy | Grant | 12,500 | $0 | 6/12/2025 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 4,793 | — | 6/6/2025 | View on chart |
| BCRX | ▲ Buy | Grant | 523 | $6K | 5/30/2025 | View on chart |
| BCRX | ▲ Buy | Grant | 653 | $6K | 2/28/2025 | View on chart |
| BCRX | ▲ Buy | Grant | 750 | $6K | 11/29/2024 | View on chart |
| BCRX | ▲ Buy | Grant | 647 | $6K | 8/30/2024 | View on chart |
| BCRX | ▲ Buy | Grant | 6,820 | $0 | 6/12/2024 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 4,660 | — | 6/1/2024 | View on chart |
| BCRX | ▲ Buy | Grant | 870 | $6K | 5/31/2024 | View on chart |
| BCRX | ▲ Buy | Open Market | 15,000 | $94K | 5/20/2024 | View on chart |
| BCRX | ▲ Buy | Grant | 999 | $6K | 2/29/2024 | View on chart |
| BCRX | ▲ Buy | Grant | 956 | $6K | 11/30/2023 | View on chart |
| BCRX | ▲ Buy | Grant | 791 | $6K | 8/31/2023 | View on chart |
| BCRX | ▲ Buy | Grant | 16,745 | $0 | 6/13/2023 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 4,507 | — | 6/2/2023 | View on chart |
| BCRX | ▲ Buy | Grant | 680 | $6K | 5/31/2023 | View on chart |
| BCRX | ▲ Buy | Grant | 635 | $6K | 2/28/2023 | View on chart |
| BCRX | ▲ Buy | Grant | 421 | $6K | 11/30/2022 | View on chart |
| BCRX | ▲ Buy | Grant | 404 | $6K | 8/31/2022 | View on chart |
| BCRX | ▲ Buy | Grant | 12,866 | $0 | 6/7/2022 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 3,356 | — | 6/3/2022 | View on chart |
| BCRX | ▲ Buy | Open Market | 7,500 | $91K | 11/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
BCRX Trades at 11x Forward Earnings, Analysts See $20.73 Target
BCRX is currently trading at about 11 times its forward earnings, which is on the lower side for the biotech sector. Analysts have an average target of $20.73, with a range from $11 to $32, while the stock sits near the bottom of its 52‑week range. This valuation gap raises questions about whether the market is pricing in potential challenges for the company.
BCRX Trades at 11x Forward Earnings, Analysts See $20.73 Target. BCRX is currently trading at about 11 times its forward earnings, which is on the lower side for the biotech sector. Analysts have an average target of $20.73, with a range from $11 to $32, while the stock sits near the bottom of its 52‑week range. This valuation gap raises questions about whether the market is pricing in potential challenges for the company.